Pfizer BioNTech

Earlier this week, Pfizer and its partner BioNTech applied for authorization for a two-dose regimen at the FDA’s request, even though officials announced in December that two shots did not produce a sufficient immune response in children ages 2 to 4. However, there are trials still underway for a third dose, but data will not […]